31676-55-8

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Hydroxy-5-phenylpyridine is utilized as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure allows it to serve as a building block for creating new and effective medications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Hydroxy-5-phenylpyridine is recognized for its pharmacological properties, making it a valuable compound for research and development. Its potential applications in this area contribute to the advancement of new therapeutic agents.
Used in Drug Development:
Identified as a potential scaffold for drug development, 3-Hydroxy-5-phenylpyridine plays a significant role in the pharmaceutical industry. Its incorporation into drug design facilitates the creation of innovative and effective treatments for various medical conditions.

InChI:InChI=1/C11H9NO/c13-11-6-10(7-12-8-11)9-4-2-1-3-5-9/h1-8,13H

Upstream product

• 7732-18-5 water 
• 142137-17-5 3-bromo-5-phenylpyridine 
• 74115-13-2 5-bromopyridine-3-ol 
• 100-58-3 phenylmagnesium bromide 
• 53698-52-5 3-methoxy-5-phenylpyridine 

Relevant academic research and scientific papers

P2Et Phosphazene: A Mild, Functional Group Tolerant Base for Soluble, Room Temperature Pd-Catalyzed C-N, C-O, and C-C Cross-Coupling Reactions

The non-nucleophilic organic superbase P2Et phosphazene can enable a broad range of palladium-catalyzed cross-coupling reactions, including C-C, C-N, and C-O couplings of aryl chlorides, bromides, and iodides at room temperature. The mildness a

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

Selective Co/Ti cooperatively catalyzed biaryl couplings of aryl halides with aryl metal reagents

Various aryl bromides or chlorides, including those bearing a free COOH, OH, CONHR, and SO2NHR group, coupled with aryl magnesium or lithium reagents in the presence of 7.5 mol % CoCl2/15 mol % PBu3 and substoichiometric Ti(OEt)4 (40 mol % to ArM) at room temperature in high yields with high chemo- and regioslectivity. This simple reaction represents the first example of Co/Ti cooperative catalysis which plays a key role in suppressing undesired homocouplings.

8-Azabicyclo[3.2.1]octane derivatives

The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of the 8-azabicyclo[3.2.1]octane derivative in therapy.

8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein R1 is H or C1-5alkyl; Y is O, S or O(CH2)m; m is 1 or 2; n is 0 or 1; Ar1 is phenylene or pyridylene, said phenylene and pyridylene being 1,3-linked with respect to O and when n is 1 with Y and when n is 0 with Ar2, said phenylene or pyridylene being optionally substituted with one or two substituents independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, phenyl, CN and hydroxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar2 to form a 5-membered ring; Ar2 is phenyl or a 5-6 membered heteroaryl, said phenyl or 5-6 membered heteroaryl being optionally substituted with one to three substituents independently selected from halogen, C1-5alkyl, C1-5alkoxy, CN, CONR2R3, CO2R4, NHCOR5 and hydroxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar1 to form a 5-membered ring; R2-R4 are independently H or C1-5alkyl and R5 is C1-5alkyl, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising a 8- azabicyclo[3.2.1]octane derivative according to the present invention in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of a 8- azabicyclo[3.2.1]octane derivative according to the present invention in therapy.